Laekna (HKSE:02105) Total Operating Expense: HK$407.7 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02105 Laekna Inc HKSE:02105
30 GF Score
Price HK$6.05
! 2 Warning Signs
View Full Analysis

What is Laekna Total Operating Expense?

Laekna HKSE:02105 -6.27% 30 Total Operating Expense is HK$407.7 Mil as of Dec. 2025. GuruFocus rates HKSE:02105 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Laekna's Total Operating Expense for the six months ended in Dec. 2025 was HK$251.4 Mil. Laekna's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$407.7 Mil.

Laekna Total Operating Expense Related Terms

Laekna Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Laekna's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laekna Total Operating Expense Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
275.54 439.22 334.58 308.18 386.99

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only 183.55 168.07 141.50 156.31 251.43
HKSE:02105
30GF Score
Laekna Inc HKSE:02105
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laekna Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$407.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of HK$407.7 Mil mean?
Laekna (HKSE:02105) has a Total Operating Expense of HK$407.7 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Laekna and its competitors.
Is Laekna's Total Operating Expense too high?
Laekna's current Total Operating Expense is HK$407.7 Mil. Overall, Laekna has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Laekna's Total Operating Expense compare to VRTX and REGN?
Laekna's Total Operating Expense of HK$407.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Laekna and its competitors. Laekna's current Total Operating Expense is HK$407.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laekna stock overvalued right now?
Laekna (HKSE:02105) has a current Total Operating Expense of HK$407.7 Mil. The current Total Operating Expense is HK$407.7 Mil. Laekna's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Laekna (HKSE:02105), the current Total Operating Expense is HK$407.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Laekna Business Description

Other Exchanges 4U4:Germany
Address No. 3-2-467, 5 Xingbin Road (Lin Li Center, Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers. Laekna has two Core Products and other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer.
30GF Score

Get the complete analysis for HKSE:02105

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.05
Price